Advent Therapeutics Awarded $3 Million NIH Grant for Novel Neonatal Lung Therapy

<p>Expedites Development of Non-Invasive Inhaled Bronchopulmonary Dysplasia Therapy DOYLESTOWN, Pa., July 18, 2023 (GLOBE NEWSWIRE) — Advent Therapeutics, Inc., a biotechnology company pioneering an optimized retinol palmitate (vitamin A) drug product as a breakthrough non-invasive inhaled neonatal lung therapy, has been awarded a $3 million National Institutes of Health (NIH) Small Business Innovation Research (SBIR) […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/advent-therapeutics-awarded-3-million-nih-grant-for-novel-neonatal-lung-therapy/">Advent Therapeutics Awarded $3 Million NIH Grant for Novel Neonatal Lung Therapy</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>